What is Leerink Partnrs' Estimate for ARWR FY2025 Earnings?

Key Points

• Leerink Partners has raised its FY2025 earnings estimate for Arrowhead Pharmaceuticals from $0.22 to $0.37 per share, while the current consensus estimate for the company's full-year earnings remains at ($2.42) per share.
• Arrowhead Pharmaceuticals recently reported a quarterly EPS of ($1.26), which missed analyst expectations of ($0.94), and had revenue of $27.77 million against the forecast of $29.01 million.
• Arrowhead Pharmaceuticals has a current consensus rating of "Moderate Buy" with a target price of $43.14, as several analysts have recently adjusted their ratings and price targets on the stock.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued on Thursday, August 14th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of $0.37 for the year, up from their previous forecast of $0.22. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at $0.20 EPS, FY2026 earnings at ($1.57) EPS, FY2027 earnings at ($2.80) EPS and FY2028 earnings at ($2.04) EPS.

Several other analysts have also commented on the stock. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Finally, TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Stock Up 2.8%

ARWR traded up $0.58 on Monday, hitting $21.33. The company had a trading volume of 2,646,214 shares, compared to its average volume of 2,268,002. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $27.34. The stock has a fifty day simple moving average of $17.10 and a 200-day simple moving average of $15.96. The firm has a market capitalization of $2.95 billion, a P/E ratio of -16.66 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same period in the previous year, the business earned ($1.38) EPS.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 9,389 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $20.00, for a total value of $187,780.00. Following the completion of the transaction, the insider directly owned 262,122 shares of the company's stock, valued at approximately $5,242,440. The trade was a 3.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.30% of the company's stock.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ARWR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after purchasing an additional 2,774,933 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 25.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock valued at $208,889,000 after purchasing an additional 2,222,223 shares during the last quarter. Marshall Wace LLP boosted its stake in Arrowhead Pharmaceuticals by 3,507.8% during the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company's stock valued at $34,065,000 after purchasing an additional 2,096,238 shares during the last quarter. Norges Bank purchased a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $30,414,000. Finally, Vanguard Group Inc. boosted its stake in Arrowhead Pharmaceuticals by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock valued at $168,201,000 after purchasing an additional 1,018,273 shares during the last quarter. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.